<DOC>
	<DOCNO>NCT01216696</DOCNO>
	<brief_summary>This Open-label , single-arm , phase II study ipilimumab patient spontaneous preexist immune response NY-ESO-1 . Preclinical data suggest , CTLA-4 blockade enhances polyfunctional T cell responses patient melanoma . Thus patient immunological response NY-ESO-1 might benefit anti CTLA-4 treatment . Eligible patient receive 10 mg/kg ipilimumab every 3 week 10-week induction period , follow radiological assessment week 12 . Patients clinical benefit ( partial response , complete response stable disease accord immune-related response criterion ) continue ipilimumab administration every 3 month start week 24 week 48 end study disease progression , toxicity require discontinuation</brief_summary>
	<brief_title>Ipilimumab Patients With Advanced Melanoma Spontaneous Preexisting Immune Response NY-ESO-1</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis malignant melanoma ; unresectable Stage III melanoma Stage IV melanoma ; Measurable/evaluable disease ( per mWHO criterion ) , within 28 day first dose study drug ; Preexisting spontaneous immune response NYESO1 , define positive result ELISA prespecified cutoff value . Previously treat untreated metastatic melanoma . The previous treatment must finish least 28 day first ipilimumab administration . Patients must recover acute toxicity associate prior therapy Life expectancy ≥ 16 week ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Men woman , age 18 . Ability subject understand character individual consequence clinical trial Required value initial laboratory test : WBC ≥ 2000/μL ANC ≥ 1000/μL Platelets ≥ 100 x 103/μL Hemoglobin ≥ 9 g/dL ( may transfuse ) Creatinine ≤ 2 x ULN AST/ALT ≤ 2.5 x ULN subject without liver metastasis≤ 5 x ULN subject liver metastasis Bilirubin ≤ 2.0 x ULN Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study Brain Metastasis , unless previously treat , steroid least 4 week consider stable ( eg , progression treat lesion ) ; Primary ocular mucosal melanoma Prior malignancy active within previous 5 year except locally curable cancer adequately treat , basal squamous cell skin cancer . Autoimmune disease : subject document history inflammatory bowel disease , include ulcerative colitis Crohn 's disease exclude study subject history symptomatic disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , Systemic Lupus Erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) . Subjects motor neuropathy consider autoimmune origin ( e.g. , GuillainBarre Syndrome ) exclude study Any underlying medical psychiatric condition , opinion investigator , make administration study drug hazardous obscure interpretation AEs , condition associate frequent diarrhea . Previous participation NYESO 1 derive vaccination study . Inadequate hematologic function define absolute neutrophil count ( ANC ) &lt; 1,000/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin level &lt; 9 g/dL ; Inadequate hepatic function define total bilirubin level &gt; 2.0 x ULN except subject Gilbert 's Syndrome , must total bilirubin &lt; 3.0 ULN . AST ALT level ≥ 2.5 time ULN , ≥ 5 time ULN liver metastases present ; Inadequate renal function define serum creatinine level ≥ 2.0 time ULN , inadequate creatinine clearance define less 50 mL/min ; Positive test HIV , Hepatitis B , Hepatitis C. If positive result indicative true active chronic infection , patient enter study discussion agreement investigator Medical Monitor . Chronic use immunosuppressant and/or systemic corticosteroid ( used management cancer noncancerrelated illness ) . Any nononcology vaccine therapy use prevention infectious disease ( 4 week prior dose ipilimumab ) ; Prior treatment CD137 agonist , ipilimumab CTLA4 inhibitor . Prisoners subject involuntarily incarcerate Participation clinical trial observation period compete trial , respectively last 30 day first application investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ipilimumab</keyword>
	<keyword>melanoma</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>